Inflammatory Disease News and Research

RSS

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) Elafibranor for its leading drug candidate previously referred to as GFT505.

3 Jun 2015

National Psoriasis Foundation awards grants to support psoriatic disease research

The National Psoriasis Foundation awarded eight researchers each a one-year, $75,000 Discovery Grant to support the advancement of psoriatic disease research. By gaining a better understanding of the fundamentals of psoriatic disease--what causes psoriasis and psoriatic arthritis and what happens in the body when these diseases are present--scientists can work on better treatments and a cure.

3 Jun 2015

Researchers discover new pathway that may be vital for understanding allergic asthma

Researchers at the Centenary Institute have discovered a new pathway that may be vital for our understanding allergic asthma, the most common form of asthma and the prevalent form of childhood-onset asthma affecting 2 million Australians.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

Research: Some immune cells convert into cells that trigger disease

Researchers at Case Western Reserve University School of Dental Medicine have unraveled one of the mysteries of how a small group of immune cells work: That some inflammation-fighting immune cells may actually convert into cells that trigger disease.

22 May 2015

Regulatory T cells can cure inflammatory diseases, shows research

Scientists at The University of Manchester have made an important discovery about an immune cell which is already being used in immunotherapy to treat diseases such as type I diabetes.

14 May 2015

Federal budget delivers vital funding for Australian medical research

This vital funding boost will ensure Australia remains at the forefront of cutting edge medical research, delivering the critical breakthroughs needed to understand disease and find cures.

13 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.

27 Apr 2015

NPC recognized as top ranking company on DiversityInc Top 50 Companies for Diversity list

Novartis Pharmaceuticals Corporation has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards ceremony in New York, NY.

25 Apr 2015

Adseverin protein plays key role in bone loss associated with osteoinflammatory disease

Adseverin, a protein found in the body, has been identified as the key driver behind the bone loss associated with the world's most common inflammatory disease: gum disease, or periodontitis.

23 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price.

10 Apr 2015

Study can aid in developing patient-centered interventions for seniors with asthma

Although often considered a childhood health problem, asthma - a chronic inflammatory disease that causes recurrent cough, wheezing and chest tightness or shortness of breath - can cause serious illness for people age 60 and older, and little is known about the triggers of asthma specific to seniors.

31 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

Inflammatory Disease News and Research

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

National Psoriasis Foundation awards grants to support psoriatic disease research

Researchers discover new pathway that may be vital for understanding allergic asthma

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Research: Some immune cells convert into cells that trigger disease

Regulatory T cells can cure inflammatory diseases, shows research

Federal budget delivers vital funding for Australian medical research

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

NPC recognized as top ranking company on DiversityInc Top 50 Companies for Diversity list

Adseverin protein plays key role in bone loss associated with osteoinflammatory disease

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Fewer patients take effective gout drug after steep price increase

Study can aid in developing patient-centered interventions for seniors with asthma

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News